Page 262 - 2021_06-Haematologica-web

Case Reports
References
1. CormierM,BattyP,TarrantJ,LillicrapD.Advancesinknowledgeof inhibitor formation in severe haemophilia A. Br J Haematol. 2020;189(1):39-53.
2. ScottDW,PrattKP.FactorVIII:perspectivesonimmunogenicityand tolerogenic strategies. Front Immunol. 2019;10:3078.
3. Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to fac- tors IXa and X restores factor VIII hemostatic activity in a hemophil- ia A model. Nat Med. 2012;18(10):1570-1574.
4. Sampei Z, Igawa T, Soeda T, et al. Identification and multidimen- sional optimization of an asymmetric bispecific IgG antibody mim- icking the function of factor VIII cofactor activity. PLoS One. 2013; 8(2):e57479.
5. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809-818.
6. Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811-822.
7. Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A
with inhibitors. Blood. 2019;134(24):2127-2138.
8. PipeSW,ShimaM,LehleM,etal.Efficacy,safety,andpharmacoki-
netics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-ran- domised phase 3 study. Lancet Haematol. 2019;6(6):e295-e305.
9. Harkins Druzgal C, Kizilocak H, Brown J, Sennett M, Young G. Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: new case with detailed labora- tory evaluation. J Thromb Haemost. 2020;18(9):2205-2208.
10.Valsecchi C, Gobbi M, Beeg M, et al. Characterization of the neu- tralizing anti-emicizumab antibody in a patient with hemophilia A and inhibitor. J Thromb Haemost. 2021;19(3):711-718.
11.Paz-Priel I, Chang T, Asikanius E, et al. Immunogenicity of emi- cizumab in people with hemophilia A (PwHA): results from the HAVEN 1-4 studies. Blood. 2018;132(Suppl 1):S633.
12.Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofac- tor activity of a bispecific antibody to factors IX/IXa and X/Xa, emi- cizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017;117(7):1348-1357.
13.Ferriere S, Peyron I, Christophe OD, et al. A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood. 2020;136(6):740-748.
2290
haematologica | 2021; 106(8)